GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Cyclically Adjusted Price-to-FCF

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 01, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexicon Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexicon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Lexicon Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lexicon Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Lexicon Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.206/129.4194*129.4194
=-0.206

Current CPI (Dec. 2023) = 129.4194.

Lexicon Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.413 99.695 -0.536
201406 -0.267 100.560 -0.344
201409 -0.288 100.428 -0.371
201412 -0.053 99.070 -0.069
201503 -0.227 99.621 -0.295
201506 -0.315 100.684 -0.405
201509 -0.248 100.392 -0.320
201512 2.564 99.792 3.325
201603 -0.422 100.470 -0.544
201606 -0.461 101.688 -0.587
201609 -0.339 101.861 -0.431
201612 -0.470 101.863 -0.597
201703 -0.819 102.862 -1.030
201706 -0.307 103.349 -0.384
201709 -0.322 104.136 -0.400
201712 -0.319 104.011 -0.397
201803 -0.443 105.290 -0.545
201806 -0.496 106.317 -0.604
201809 -0.210 106.507 -0.255
201812 -0.256 105.998 -0.313
201903 -0.242 107.251 -0.292
201906 -0.253 108.070 -0.303
201909 1.635 108.329 1.953
201912 -0.209 108.420 -0.249
202003 -0.207 108.902 -0.246
202006 -0.432 108.767 -0.514
202009 -0.343 109.815 -0.404
202012 -0.280 109.897 -0.330
202103 -0.176 111.754 -0.204
202106 -0.158 114.631 -0.178
202109 -0.119 115.734 -0.133
202112 -0.153 117.630 -0.168
202203 -0.158 121.301 -0.169
202206 -0.163 125.017 -0.169
202209 -0.111 125.227 -0.115
202212 -0.121 125.222 -0.125
202303 -0.169 127.348 -0.172
202306 -0.187 128.729 -0.188
202309 -0.170 129.860 -0.169
202312 -0.206 129.419 -0.206

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lexicon Pharmaceuticals  (NAS:LXRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lexicon Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Executives
Philippe Amouyal director C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats director, officer: President and CEO 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner officer: SVP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade officer: EVP, Gen. Counsel 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott officer: VP, Human Resources 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a. director, 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc director, 10 percent owner 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth officer: VP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub officer: SVP, Regulatory & QA 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander officer: VP, Finance and Accounting 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz officer: SVP, Chief Medical Officer 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer officer: VP, Finance & Acctg 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381